Detail akcie Rapd Micro Bio Rg-A online

Business Summary: Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission-critical automation solutions to facilitate the manufacturing and release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Its flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Rapid Micro Biosystems Inc revenues increased 12% to $22.3M. Net loss decreased 7% to $34.6M. Revenues reflect Service revenue segment increase of 27% to $8.9M, Product revenue segment increase of 4% to $13.4M, Germany segment increase from $2.4M to $4.9M, Japan segment increase of 67% to $2.3M. Lower net loss reflects Sales and marketing - Balancing value decrease of 16% to $8.2M (expense).